Poseida Therapeutics Overview

Poseida Therapeutics Cost of Revenue

Cost of Revenue analysis for PSTX.

Quarterly Cost of Revenue

N/A

As of Sep 30, 2024

Annual Cost of Revenue (TTM)

$6.91M

↑ 65.35% YoY

Trailing 12 months ending Sep 30, 2024

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin